TRASYLOL

This brand name is authorized in Austria, Finland, France, Ireland, Malta, New Zealand, Poland, Romania, Singapore, South Africa, Turkey.

Active ingredients

The drug TRASYLOL contains one active pharmaceutical ingredient (API):

1	Aprotinin UNII 04XPW8C0FL - APROTININ
	Aprotinin is a broad spectrum protease inhibitor which has antifibrinolytic properties. By forming reversible stoichiometric enzyme-inhibitor complexes, aprotinin acts as an inhibitor of human trypsin, plasmin, plasma kallikrein and tissue kallikrein, thus inhibiting fibrinolysis.
	Read more about Aprotinin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02AB01	Aprotinin	B Blood and blood forming organs → B02 Antihemorrhagics → B02A Antifibrinolytics → B02AB Proteinase inhibitors
Discover more medicines within B02AB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FI	Lääkealan turvallisuus- ja kehittämiskeskus	447982
FR	Base de données publique des médicaments	65436166
MT	Medicines Authority	AA1411/00401
NZ	Medicines and Medical Devices Safety Authority	1222
PL	Rejestru Produktów Leczniczych	100129127
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68337001
SG	Health Sciences Authority	07805P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699546691289
ZA	Health Products Regulatory Authority	H/32/2912